KD TCR75
Alternative Names: KD-TCR75Latest Information Update: 28 May 2024
At a glance
- Originator Nanjing KAEDI Biotech
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 29 Apr 2020 KD TCR75 is available for licensing as of 29 Apr 2020. http://www.cartbiomed.com/
- 29 Apr 2020 Preclinical trials in Cancer in China (Parenteral) (Nanjing KAEDI Biotech pipeline, April 2020)